Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 12, 2016 7:33 PM ET


Company Overview of Cytonics Corporation

Company Overview

Cytonics Corporation is a research and development company developing molecular diagnostic and therapeutic products for chronic orthopaedic and musculoskeletal diseases. It offers biotechnology based treatments for osteoarthritis and back and joint pain. The company’s products include autologous platelet-integrated concentrate (APIC) and autologous cell-free alpha-2-macroglobulin (a2M) concentrates. Cytonics Corporation was founded in 2006 and is headquartered in Jupiter, Florida.

555 Heritage Drive

Jupiter, FL 33458

United States

Founded in 2006





Key Executives for Cytonics Corporation

Founder, President, and Member of Board of Directors
Vice President of Research and Development
Compensation as of Fiscal Year 2015.

Cytonics Corporation Key Developments

Cytonics Corporation Announces Investigational New Drug (IND) Application for a Phase I/II Clinical Trial

Cytonics Corporation has announced that an Investigational New Drug (IND) application for a phase I/II clinical trial of the company's APIC Cell-Free System has been approved by the FDA. The system is indicated for the rapid preparation of concentrated protease inhibitors in plasma, specifically Alpha-2-Macroglobulin (A2M), for the treatment of mild to moderate osteoarthritis (OA) in the knee. This novel system concentrates A2M from a patient's own blood for direct injection into a joint that shows early signs of OA. The system is expected to be the first treatment for OA that can inhibit well known causes of cartilage breakdown and thereby prevent cartilage loss, reduce pain, and stop the progression of OA, as demonstrated by the company's research.

Similar Private Companies By Industry

Company Name Region
Coeurative, Inc. United States
ViaCyte, Inc. United States
CytRx Oncology Corporation United States
Shire Biologics, Inc. United States
Tolero Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cytonics Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at